The Administrative Core will be responsible for the managerial oversight of all Johns Hopkins Prostate SPORE Program activities. In addition, the Core will help facilitate interactions between Johns Hopkins Prostate Cancer SPORE Program Investigators and investigators associated with other Prostate Cancer initiatives. The managerial structure of Johns Hopkins Prostate Cancer SPORE Program, with Its Principal Investigator, Co-Principal Investigator, Executive Committee, Internal Oversight Committee, and External Scientific Advisory Board, has been designed to promote translational research by creating a prostate cancer research culture and transcends academic departments, medical disciplines, and individual research skills, and providing high quality monitoring, evaluation, and oversight of the SPORE portfolio of Research Projects, Core Resources, the Career Development Program, and the Developmental Research Program. The Administrative Core will provide communications, resources, including teleconferences, travel funds, and administrative staffing for all its managerial activities.
Prostate cancer remains the leading cause of cancer of men in the United States. This Core provides for a coordination and facilitation of efforts to bring novel therapeutic approaches to the disease as well as biomarkers that can provide disease signatures.
|Regter, Sietze; Hedayati, Mohammad; Zhang, Yonggang et al. (2014) Androgen withdrawal fails to induce detectable tissue hypoxia in the rat prostate. Prostate 74:805-10|
|Ku, ShengYu; Lasorsa, Elena; Adelaiye, Remi et al. (2014) Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer. PLoS One 9:e103680|
|Chalfin, Heather J; Frank, Steven M; Feng, Zhaoyong et al. (2014) Allogeneic versus autologous blood transfusion and survival after radical prostatectomy. Transfusion 54:2168-74|
|Bhatnagar, Akrita; Wang, Yuchuan; Mease, Ronnie C et al. (2014) AEG-1 promoter-mediated imaging of prostate cancer. Cancer Res 74:5772-81|
|Brennen, W Nathaniel; Rosen, D Marc; Chaux, Alcides et al. (2014) Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. Prostate 74:1308-19|
|Paller, C J; Olatoye, D; Xie, S et al. (2014) The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis 17:28-33|
|Durham, Nicholas M; Nirschl, Christopher J; Jackson, Christopher M et al. (2014) Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS One 9:e109080|
|Gurel, Bora; Lucia, M Scott; Thompson Jr, Ian M et al. (2014) Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 23:847-56|
|Lutz, Eric R; Wu, Annie A; Bigelow, Elaine et al. (2014) Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2:616-31|
|Zheng, Qizhi; Peskoe, Sarah B; Ribas, Judit et al. (2014) Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy. Prostate 74:1655-62|
Showing the most recent 10 out of 579 publications